17 December 2019

LAST PATIENT COMPLETES DOSING IN ZELIRA'S INSOMNIA CLINICAL TRIAL

- ***Patient dosing completed in Australia's first clinical trial of medicinal cannabis to treat insomnia***
- ***No serious adverse event reported to-date***
- ***Interim results expected by February 2020***

Zelira Therapeutics Limited (ASX: ZLD, OTCQB: ZLDAF) is pleased to advise the last patient has completed dosing in its pioneering medicinal cannabis trial for insomnia. It was noted no serious adverse events have been reported to-date. Zelira expects to provide interim results for the trial by February 2020.

The insomnia trial is led by the prestigious University of Western Australia (UWA) Centre for Sleep Science (CSS) and is evaluating the safety and efficacy of a cannabinoid extract containing THC and CBD in patients with symptoms of clinically diagnosed chronic insomnia. The primary endpoint of the trial is to assess the impact of a full-spectrum cannabis extract on sleep.

An estimated 70 million Americans have insomnia where the market for prescription and over-the-counter medications used to treat the condition generates over US$2 billion in annual revenue. Zelira is leading the development of clinically validated full spectrum cannabis medicines to access global markets for insomnia medications.

Tim Slate
Company Secretary

About Zelira Therapeutics (www.zeliratx.com)

Zelira Therapeutics Ltd is a leading global therapeutic medicinal cannabis company with access to the world's largest and fastest growing cannabis markets. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets from 2020. The company is focused on developing branded cannabis products for the treatment of a variety of medical conditions.

The Company is undertaking:

- **Human clinical trial programs** focused on insomnia, autism and opioid reduction with activities in Australia and the USA.
- **Pre-clinical research** examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

The Company conducts this work in partnership with world-leading researchers and organizations including Complutense University in Madrid, Spain; Curtin University in Perth, Western Australia; the Telethon Kids Institute in Perth; the University of Western Australia, in Perth; St. Vincent's Hospital in Melbourne, Australia; and the Children's Hospital of Philadelphia (CHOP) in the United States.

Zelira has also formed a strategic partnership with European medicinal cannabis group HAPA Pharm BV, to access HAPA Pharm's EU-GMP grade manufacturing capabilities and accessing its German distribution network providing a credible and rapid path to commercialization for successful clinically validated formulations.

The Company has developed two proprietary formulations (HOPE®) already launched and generating revenues in Pennsylvania, has laboratory capabilities to develop formulations in Pennsylvania and Louisiana with ability to conduct clinical trials and is establishing a national footprint across the US for the licensing of its products. The company also has a partnership with Ethicann for the development of a proprietary product, CAN-001, which is being developed for the treatment of chemotherapy-induced nausea and vomiting (CINV), which occurs in approximately 80% of the new 23.6 million cases of cancer annually worldwide.

###

Address
Level 26
140 St Georges Terrace, Perth WA 6000 AUSTRALIA
Tel: +61 8 6558 0886
Fax: +61 8 6316 3337
E: enquiries@zeldatherapeutics.com
W: www.zeliratx.com
ACN 103 782 378

Tickers
Australia (ASX): ZLD USA
(OTCQB): ZLDAF

Australia Contact
Dr Richard Hopkins
Managing Director & CEO, Ex USA
+61 405 656 868
rhopkins@zeldatherapeutics.com

Monsoon Communications
Rudi Michelson
+61 3 9620 3333
rudim@monsoon.com

U.S. Contacts:
Dr. Oludare Odumosu
Managing Director & CEO, USA
+1-909-855-0675
oodumosu@zeliratx.com
3553 West Chester Pike #110,
Newtown Square, PA 19073

GVM Communications, Inc.
Gia Morón,
347-678-8079 |
gia@gvmcommsinc.com